Reported revenues of $227.2m, down 17% on 1HFY19
• Reported EBITDA of $34.6m, a decrease of 47% on 1HFY19
• Underlying EBITDA of $47.4m, a decrease of 42% on 1HFY19
• Reported net loss after tax of $17.5m driven by lower earnings and restructuring expenses
• Net operating cashflow of $46.2m down 14% on 1HFY19
• Licensed novel oral contraceptive E4/DRSP in the US
• Generic NUVARING® complete response letter submitted to the US Food and Drug
Administration (FDA) with launch anticipated in CY20
• Filed three generic products with the FDA including a potential first-to-market women’s health
product
• Significant spend base reduction of $20m (annualised)
Ann: 2020 Half Year Media Release, page-2
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.38 |
Change
0.440(11.2%) |
Mkt cap ! $372.6M | |||
| Open | High | Low | Value | Volume |
| $4.40 | $4.79 | $4.18 | $2.649M | 590.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1271 | $4.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.44 | 1271 | 1 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| MYX (ASX) Chart |